

Ioannis E Koutroubakis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3723455/publications.pdf>

Version: 2024-02-01

210
papers

7,888
citations

61687

45
h-index

68831

81
g-index

219
all docs

219
docs citations

219
times ranked

8093
citing authors

#	ARTICLE	IF	CITATIONS
1	Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 228-237.	0.9	4
2	Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 70-78.	0.9	11
3	Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 641.	1.0	6
4	Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2022, 37, 639-646.	1.0	0
5	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
6	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	2.4	9
7	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	0.6	5
8	Clinical Characteristics of Inflammatory Bowel Disease Patients Requiring Long-Term Parenteral Support in the Present Era of Highly Effective Biologic Therapy. <i>Journal of Parenteral and Enteral Nutrition</i> , 2021, 45, 1100-1107.	1.3	4
9	Mucocutaneous manifestations in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, 1387-1393.	0.8	2
10	Reply to the letter to the Editor: "The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease". <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 300-302.	0.8	0
11	Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. <i>Gastroenterology</i> , 2021, 160, 1452-1460.e21.	0.6	68
12	The burden and management of anemia in Greek patients with inflammatory bowel disease: a retrospective, multicenter, observational study. <i>BMC Gastroenterology</i> , 2021, 21, 269.	0.8	8
13	Extra-pleural Solitary Fibrous Tumor of the Pelvis in a Patient with Crohn's Disease Under Anti-TNF: A Case Report. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e55-e56.	0.9	1
14	Is there any role of renin-angiotensin system inhibitors in modulating inflammatory bowel disease outcome?. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, 364-371.	0.8	12
15	Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?. <i>Intestinal Research</i> , 2021, 19, 461-467.	1.0	5
16	Osteoclast: like giant cell undifferentiated pancreatic tumor diagnosed by means of EUS guided FNA. <i>Acta Biomedica</i> , 2021, 92, e2021106.	0.2	1
17	Solid extraintestinal malignancies in patients with inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1956-1980.	0.8	5
18	Comparison of the Uptake of Screening Colonoscopy between Physicians and the General Population in Greece. <i>Digestive Diseases</i> , 2020, 38, 23-30.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 480-489.	0.6	26
20	Opioid Analgesics Do Not Improve Abdominal Pain or Quality of Life in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2379-2387.	1.1	20
21	Keeping on the High Quality of Health Care in Greek Inflammatory Bowel Disease Patients in the SARS-CoV-2 Era. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2380-2381.	2.4	4
22	Clinical Value of Proactive Infliximab Drug Monitoring in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e50.	0.9	0
23	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1381-1392.	2.4	161
24	Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1436-1442.	0.9	20
25	Peripheral Blood Eosinophilia and Long-term Severity in Pediatric-Onset Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1890-1900.	0.9	10
26	The role of coexisting cardiovascular disease on disease severity in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 581-587.	0.8	4
27	Iron Sucrose: A Wealth of Experience in Treating Iron Deficiency. <i>Advances in Therapy</i> , 2020, 37, 1960-2002.	1.3	11
28	Aortic Stiffening Is an Extraintestinal Manifestation of Inflammatory Bowel Disease: Review of the Literature and Expert Panel Statement. <i>Angiology</i> , 2020, 71, 689-697.	0.8	19
29	Pyoderma gangrenosum associated with chronic refractory pouchitis: a case successfully treated with infliximab. <i>Annals of Gastroenterology</i> , 2020, 33, 433-435.	0.4	0
30	Management of Patients with Inflammatory Diseases during the COVID-19 Pandemic. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 295.	0.3	1
31	Letter to the Editor: Is There a Role for Switching Infliximab in Order to Regain Anti-TNF Response in Cases With Active Inflammatory Bowel Disease?. <i>Inflammatory Bowel Diseases</i> , 2019, 25, e120-e120.	0.9	0
32	Risk Factors of Colectomy in Patients With Refractory Ulcerative Colitis Under Calcineurin Inhibitors Combined With Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1213-1214.	2.4	0
33	Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 187-191.	0.8	12
34	Prevalence of Clostridium difficile infection among hospitalized inflammatory bowel disease patients in Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 773-776.	0.8	8
35	Inflammatory Bowel Disease [IBD] and Physical Activity: A Study on the Impact of Diagnosis on the Level of Exercise Amongst Patients With IBD. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 686-692.	0.6	29
36	Fecal Calprotectin in Assessing Inflammatory Bowel Disease Endoscopic Activity: a Diagnostic Accuracy Meta-analysis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 27, 299-306.	0.5	82

#	ARTICLE	IF	CITATIONS
37	Ileocecal Anastomosis Type Significantly Influences Long-Term Functional Status, Quality of Life, and Healthcare Utilization in Postoperative Crohn's Disease Patients Independent of Inflammation Recurrence. <i>American Journal of Gastroenterology</i> , 2018, 113, 576-583.	0.2	40
38	Epithelioid Granulomas Associate With Increased Severity and Progression of Crohn's Disease, Based on 6-Year Follow-Up. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 900-907.e1.	2.4	26
39	Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients. <i>Digestive Diseases and Sciences</i> , 2018, 63, 2729-2739.	1.1	11
40	Asymptomatic hyperCKemia During Infliximab Therapy in Patients With Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1266-1271.	0.9	8
41	Development of an index to define overall disease severity in IBD. <i>Gut</i> , 2018, 67, 244-254.	6.1	108
42	Quality of Sleep and Coexistent Psychopathology Have Significant Impact on Fatigue Burden in Patients With Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 423-430.	1.1	33
43	Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients. <i>Journal of Clinical Gastroenterology</i> , 2018, 52, 319-325.	1.1	3
44	Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1037-1038.	1.9	0
45	The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1380-1388.	0.9	31
46	Use of vedolizumab in a patient with chronic and refractory pouchitis. <i>Annals of Gastroenterology</i> , 2018, 31, 379.	0.4	6
47	Reply - Fecal calprotectin correlates well with endoscopic activity in ulcerative colitis patients. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 474-475.	0.5	0
48	Poor Consumption of Fiber, not fat, is Associated with Active Disease in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 152, S365.	0.6	0
49	Lasting Impact of Clostridium difficile Infection in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 2180-2188.	0.9	26
50	Prevalence of thiopurine S-methyltransferase gene polymorphisms in patients with inflammatory bowel disease from the island of Crete, Greece. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1284-1289.	0.8	4
51	Is High Globulin Fraction a Biomarker of Severity in Inflammatory Bowel Disease (IBD)? Analysis of a 6-Year, Prospective Natural History Registry. <i>Gastroenterology</i> , 2017, 152, S372.	0.6	0
52	Variation in Annual Rate of Steroid Prescriptions Amongst Providers for Inflammatory Bowel Disease Patients is Dependent on Cohort Size and Disease Severity. <i>Gastroenterology</i> , 2017, 152, S792.	0.6	0
53	The Cost of Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 107-115.	0.9	24
54	Peripheral Eosinophilia in Patients With Inflammatory Bowel Disease Defines an Aggressive Disease Phenotype. <i>American Journal of Gastroenterology</i> , 2017, 112, 1849-1858.	0.2	41

#	ARTICLE	IF	CITATIONS
55	Routine Measurement of Quality of Life in Inflammatory Bowel Disease Predicts Future Health Outcomes. <i>American Journal of Gastroenterology</i> , 2016, 111, S270.	0.2	0
56	Five-Year Period Prevalence and Characteristics of Anemia in a Large US Inflammatory Bowel Disease Cohort. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 638-643.	1.1	35
57	Delineation of Crohn's Disease Trajectories Using Change in C-reactive Protein Index. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 476-482.	1.1	13
58	Chemerin, visfatin, and vaspin serum levels in relation to bone mineral density in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 814-819.	0.8	36
59	Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1442-1449.	0.9	72
60	Multiyear Patterns of Serum Inflammatory Biomarkers and Risk of Colorectal Neoplasia in Patients with Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 100-105.	0.9	14
61	162 Investigating the Effect of Granulomatous Inflammation on Bowel Damage in Patients With Crohn's Disease: A Natural History Study. <i>Gastroenterology</i> , 2016, 150, S41.	0.6	0
62	1123 Investigating the Changes in Atherosclerotic Cardiovascular Risk Profile of IBD Patients Over 6 Years. <i>Gastroenterology</i> , 2016, 150, S226.	0.6	0
63	Correlation of anemia status with worsening bowel damage as measured by C-reactive Protein Index in patients with Crohn's disease. <i>Digestive and Liver Disease</i> , 2016, 48, 626-631.	0.4	9
64	Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e181.	1.3	14
65	Development of an Inflammatory Bowel Disease Research Registry Derived from Observational Electronic Health Record Data for Comprehensive Clinical Phenotyping. <i>Digestive Diseases and Sciences</i> , 2016, 61, 3236-3245.	1.1	28
66	Lymphangiogenesis in Inflammatory Bowel Disease; A New Therapeutic Target?. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e154.	1.3	2
67	Silent Crohn's Disease Predicts Increased Bowel Damage During Multiyear Follow-up. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2665-2671.	0.9	27
68	IBD LIVE Case Series—Case 6. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2754-2764.	0.9	2
69	Response to van den Heuvel et al.. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1374-1374.	0.6	0
70	Su1810 Clostridium difficile Infection in Inflammatory Bowel Disease Predicts Future Healthcare Utilization. <i>Gastroenterology</i> , 2016, 150, S559.	0.6	1
71	Tu1946 Can We Phenotype IBD Patients Based on Financial Charges Over Time? Trajectory Modeling of Healthcare Utilization in a Large, Prospective IBD Cohort. <i>Gastroenterology</i> , 2016, 150, S986-S987.	0.6	1
72	Sa1954 Sickest of the Sick: When Anti-TNF Agents Fail to Halt Progression of Bowel Damage in Crohn's Disease Over Time. <i>Gastroenterology</i> , 2016, 150, S415.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Sa1876 Do Epithelioid Granulomas Function As a Biomarker of Severity in Crohn's Disease? Analysis of a Prospective Six-Year Natural History Registry. <i>Gastroenterology</i> , 2016, 150, S387-S388.	0.6	1
74	Tu1932 Long Term Implications of Achieving and Retaining Remission in Crohn's Disease as Defined by Harvey Bradshaw Index. <i>Gastroenterology</i> , 2016, 150, S981.	0.6	0
75	Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel. <i>Gastroenterology</i> , 2016, 150, S991.	0.6	0
76	Prevalence and Characteristics of Extra-intestinal Manifestations in a Large Cohort of Greek Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 429-436.	0.6	106
77	Association Between Long-Term Lipid Profiles and Disease Severity in a Large Cohort of Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2016, 61, 865-871.	1.1	42
78	European experience with methotrexate treatment in Crohn's disease: a multicenter retrospective analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 802-806.	0.8	7
79	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease—the Unmet Needs. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 758-765.	0.6	49
80	Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 712-719.	0.2	156
81	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	0.6	577
82	Analysis of Hospital-Based Emergency Department Visits for Inflammatory Bowel Disease in the USA. <i>Digestive Diseases and Sciences</i> , 2016, 61, 389-399.	1.1	53
83	Distinct features of circulating microparticles and their relationship with disease activity in inflammatory bowel disease. <i>Annals of Gastroenterology</i> , 2016, 29, 180-7.	0.4	3
84	Peripheral Blood Eosinophilia as a Potential Marker of Bowel Damage Progression in Crohn's Disease a 5 Year Natural History Study. <i>American Journal of Gastroenterology</i> , 2016, 111, S287.	0.2	0
85	Comparative Effectiveness of Common Immunomodulator Agents over 5 Year Clinical Outcomes in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, S293-S294.	0.2	0
86	Patterns of Antibiotic Exposure and Clinical Disease Activity in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2576-2582.	0.9	13
87	Sa1144 Association Between Surgical Anastomotic Technique and Postoperative Healthcare Financial Burden in Patients With Crohn's Disease: A Longterm, Prospective Study. <i>Gastroenterology</i> , 2015, 148, S-239.	0.6	3
88	Silent Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	0.9	40
89	Impact of Obesity on the Management and Clinical Course of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 2857-2863.	0.9	129
90	The Influence of Anti-tumor Necrosis Factor Agents on Hemoglobin Levels of Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1587-1593.	0.9	33

#	ARTICLE	IF	CITATIONS
91	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 211-222.	0.6	425
92	The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 479-488.	1.3	11
93	Persistent or Recurrent Anemia Is Associated With Severe and Disabling Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1760-1766.	2.4	62
94	Su1334 Eosinophilia in Patients With Inflammatory Bowel Disease Is Independently Associated With Increased Healthcare Expenditures: A Prospective 5-Year Experience. <i>Gastroenterology</i> , 2015, 148, S-477-S-478.	0.6	1
95	Anal adenocarcinoma complicating chronic Crohn's disease. <i>International Journal of Surgery Case Reports</i> , 2015, 10, 201-203.	0.2	14
96	Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. <i>Annals of Gastroenterology</i> , 2015, 28, 417-25.	0.4	5
97	Multipotent role of platelets in inflammatory bowel diseases: A clinical approach. <i>World Journal of Gastroenterology</i> , 2014, 20, 3180.	1.4	74
98	Prevalence of Anemia in Inflammatory Bowel Diseases in European Countries. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 936-945.	0.9	129
99	Ulcerative colitis and Budd-Chiari syndrome. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1306.	0.8	2
100	The Bone and Fat Connection in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 2207-2217.	0.9	10
101	Reply to Polyzos and Kountouras. <i>Inflammatory Bowel Diseases</i> , 2014, 20, E22-E23.	0.9	0
102	Gastric non-Hodgkin's lymphoma. <i>Annals of Gastroenterology</i> , 2014, 27, 167.	0.4	0
103	Cornelia de Lange syndrome in association with ulcerative colitis: A case report. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e399-e400.	0.6	1
104	Increased Fracture Risk Assessed by Fracture Risk Assessment Tool in Greek Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 216-221.	1.1	6
105	Risk of Venous Thromboembolism in Patients with Inflammatory Bowel Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 461-468.	1.5	44
106	Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 1.	0.8	31
107	Advances in the Management of Inflammatory Bowel Disease. , 2013, , .		0
108	The Janus Tyrosine Kinase-2 V617F Mutation is Not Implicated in the Pathogenesis of Ischemic Colitis in Young Patients. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 433-434.	1.1	0

#	ARTICLE	IF	CITATIONS
109	Eosinophilic gastroenteritis associated with Churg-Strauss syndrome. <i>Annals of Gastroenterology</i> , 2012, 25, 164.	0.4	3
110	Budesonide 9 mg Is at Least as Effective as Mesalamine 4.5 g in Patients With Mildly to Moderately Active Crohn's Disease. <i>Gastroenterology</i> , 2011, 140, 425-434.e1.	0.6	82
111	Measurement of reticulocyte and red blood cell indices in the evaluation of anemia in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 295-300.	0.6	50
112	Diagnosing anemia in inflammatory bowel disease: Beyond the established markers. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 381-391.	0.6	72
113	Autoimmune pancreatitis. A rare cause of cholestasis. <i>Digestive and Liver Disease</i> , 2011, 43, e3.	0.4	0
114	Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 262-268.	0.8	68
115	Role of Ghrelin and Insulin-like Growth Factor Binding Protein-3 in the Development of Osteoporosis in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e60-e65.	1.1	14
116	Antiglycan Antibodies in Greek Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2011, 56, 845-852.	1.1	7
117	New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E8-E9.	0.9	10
118	Soluble transferrin receptor-ferritin index is the most efficient marker for the diagnosis of iron deficiency anemia in patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2011, 17, E158-E159.	0.9	29
119	Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 165-173.	3.2	19
120	Acute Generalized Exanthematous Pustulosis Induced by Azathioprine in a Patient With Ulcerative Colitis. <i>American Journal of Gastroenterology</i> , 2011, 106, 1005-1007.	0.2	4
121	Soluble transferrin receptor-ferritin index in the evaluation of anemia in inflammatory bowel disease: a case-control study. <i>Annals of Gastroenterology</i> , 2011, 24, 108-114.	0.4	34
122	Low bone mineral density in Greek patients with inflammatory bowel disease: prevalence and risk factors. <i>Annals of Gastroenterology</i> , 2011, 24, 41-46.	0.4	9
123	New Editorial Board - a new start. <i>Annals of Gastroenterology</i> , 2011, 24, 8.	0.4	0
124	Anti-TNF and Fistulising Perianal Crohns Disease: Use in Clinical Practice. <i>Current Drug Targets</i> , 2010, 11, 187-197.	1.0	7
125	Which patients with IBD are at risk of venous thromboembolism?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 307-308.	8.2	2
126	Safety and Efficacy of Total-Dose Infusion of Low Molecular Weight Iron Dextran for Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2327-2331.	1.1	44

#	ARTICLE	IF	CITATIONS
127	Increased expression of chemokine receptor CCR3 and its ligands in ulcerative colitis: the role of colonic epithelial cells in <i>in vitro</i> studies. <i>Clinical and Experimental Immunology</i> , 2010, 162, 337-347.	1.1	41
128	A case of orbital myositis preceding the intestinal symptoms of Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 349-350.	0.6	16
129	Disease activity and venous thromboembolism in inflammatory bowel disease. <i>Lancet, The</i> , 2010, 375, 1689.	6.3	1
130	Recent advances in the management of distal ulcerative colitis. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2010, 1, 43.	0.6	28
131	Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 283-288.	0.8	46
132	Role of scintigraphy in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2693.	1.4	28
133	Leptin, adiponectin, resistin, and ghrelin – Implications for inflammatory bowel disease. <i>Molecular Nutrition and Food Research</i> , 2008, 52, 855-866.	1.5	87
134	JAK2 V617F mutation is not involved in thromboembolism in IBD. <i>Inflammatory Bowel Diseases</i> , 2008, 14, 1606-1607.	0.9	10
135	Allelic polymorphism in IL-1 β and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. <i>Clinical and Experimental Immunology</i> , 2008, 102, 379-383.	1.1	182
136	Small bowel perforation due to non-Hodgkin-lymphoma in a patient with ulcerative colitis and systemic lupus erythematosus. <i>Digestive and Liver Disease</i> , 2008, 40, 144.	0.4	8
137	Increased expression of VEGF and CD146 in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2008, 40, 673-679.	0.4	40
138	Genetic Risk Factors in Young Patients With Ischemic Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 907-911.	2.4	21
139	Disseminated tuberculosis in a Crohn's disease patient on anti-TNF α therapy despite chemoprophylaxis. <i>Gut</i> , 2008, 57, 425-425.	6.1	8
140	Venous Thromboembolism in Hospitalized Inflammatory Bowel Disease Patients: The Magnitude of the Problem Is Staggering. <i>American Journal of Gastroenterology</i> , 2008, 103, 2281-2283.	0.2	14
141	Active inflammatory bowel disease: head-to-head comparison between 99mTc-hexamethylpropylene amine oxime white blood cells and 99mTc(V)-dimercaptosuccinic acid scintigraphy. <i>Nuclear Medicine Communications</i> , 2008, 29, 27-32.	0.5	14
142	Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 912-916.	0.8	37
143	Thrombosis and inflammatory bowel disease-the role of genetic risk factors. <i>World Journal of Gastroenterology</i> , 2008, 14, 4440.	1.4	45
144	Spectrum of non-inflammatory bowel disease and non-infectious colitis. <i>World Journal of Gastroenterology</i> , 2008, 14, 7277.	1.4	14

#	ARTICLE	IF	CITATIONS
145	Ischemic colitis: Clinical practice in diagnosis and treatment. World Journal of Gastroenterology, 2008, 14, 7302.	1.4	216
146	Is there a role for Tc-99m (V) DMSA scintigraphy in ischemic colitis?. World Journal of Gastroenterology, 2008, 14, 5432.	1.4	6
147	The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2007, 19, 789-794.	0.8	47
148	Resistin: another rising biomarker in inflammatory bowel disease?. European Journal of Gastroenterology and Hepatology, 2007, 19, 1035-1037.	0.8	9
149	Stimulating erythropoiesis in inflammatory bowel disease associated anemia. World Journal of Gastroenterology, 2007, 13, 4798.	1.4	35
150	Antibodies Against Cyclic Citrullinated Peptide (CCP) in Inflammatory Bowel Disease Patients With or Without Arthritic Manifestations. Inflammatory Bowel Diseases, 2007, 13, 504-505.	0.9	11
151	Genetic Risk Factors In Patients With Inflammatory Bowel Disease And Vascular Complications: Case-Control Study. Inflammatory Bowel Diseases, 2007, 13, 410-415.	0.9	47
152	Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#. Inflammatory Bowel Diseases, 2007, 13, 1545-1553.	0.9	373
153	Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clinical and Experimental Immunology, 2007, 103, 391-396.	1.1	133
154	The patient with persistent perianal fistulae. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 503-518.	1.0	4
155	Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study. European Journal of Gastroenterology and Hepatology, 2006, 18, 421-425.	0.8	37
156	Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. European Journal of Clinical Investigation, 2006, 36, 127-132.	1.7	40
157	Treatment of anaemia in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2006, 23, 1273-1274.	1.9	6
158	Role of angiogenesis in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 515-523.	0.9	95
159	Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflammatory Bowel Diseases, 2006, 12, 100-105.	0.9	259
160	Inherited Thrombophilia and Thrombosis in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2006, 101, 403-403.	0.2	2
161	The Emerging Role of Adipocytokines as Inflammatory Mediators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2005, 11, 847-855.	0.9	59
162	The spectrum of segmental colitis associated with diverticulosis. International Journal of Colorectal Disease, 2005, 20, 28-32.	1.0	82

#	ARTICLE	IF	CITATIONS
163	Pancreatic Autoantibodies in Greek Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2330-2334.	1.1	18
164	Phenotype at diagnosis predicts recurrence rates in Crohn's disease. <i>Gut</i> , 2005, 55, 1124-1130.	6.1	207
165	Therapy Insight: vascular complications in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 266-272.	1.7	80
166	Hypercoagulable States in Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2004, 49, 854-858.	1.1	43
167	Decreased Total and Corrected Antioxidant Capacity in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1433-1437.	1.1	96
168	Serum Angiogenin in Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1758-1762.	1.1	49
169	Treatment of oesophageal Crohn's disease with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 431-432.	0.8	11
170	Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 1147-1152.	0.8	33
171	Low plasma protein Z levels in patients with ischemic colitis. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1673-1676.	1.1	13
172	Increased serum levels of YKL-40 in patients with inflammatory bowel disease. <i>International Journal of Colorectal Disease</i> , 2003, 18, 254-259.	1.0	72
173	A case of sigmoid endometriosis difficult to differentiate from colon cancer. <i>BMC Gastroenterology</i> , 2003, 3, 18.	0.8	50
174	Serum laminin and collagen IV in patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2003, 124, A202-A203.	0.6	1
175	Hypercoagulable states in patients with hepatocellular carcinoma. <i>Gastroenterology</i> , 2003, 124, A563-A564.	0.6	0
176	NOD2 insertion mutation in a cretan Crohn's disease population. <i>Gastroenterology</i> , 2003, 124, 272-273.	0.6	27
177	Low plasma protein Z levels in patients with colon ischemia. <i>Gastroenterology</i> , 2003, 124, A189.	0.6	0
178	New imaging techniques: promise or passe. <i>Gut</i> , 2003, 52, 1072-1072.	6.1	0
179	Transient ischaemic colitis following an aeroplane flight. <i>Gut</i> , 2003, 52, 1072-a-1073.	6.1	1
180	Serum laminin and collagen IV in inflammatory bowel disease. <i>Journal of Clinical Pathology</i> , 2003, 56, 817-820.	1.0	42

#	ARTICLE	IF	CITATIONS
181	Active Inflammatory Bowel Disease: Evaluation with ^{99m} Tc (V) DMSA Scintigraphy. <i>Radiology</i> , 2003, 229, 70-74.	3.6	25
182	Acquired and hereditary thrombotic risk factors in patients with acute mesenteric vein thrombosis. <i>American Journal of Gastroenterology</i> , 2002, 97, 768-769.	0.2	3
183	Acquired inhibitors to coagulation factors in patients with gastrointestinal diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 1383-1387.	0.8	33
184	Circulating soluble vascular adhesion protein 1 in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 405-408.	0.8	10
185	Colonic tuberculosis mimicking Crohn's disease: case report. <i>BMC Gastroenterology</i> , 2002, 2, 10.	0.8	29
186	Role of Appendicitis and Appendectomy in the Pathogenesis of Ulcerative Colitis: A Critical Review. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 277-286.	0.9	125
187	^{99m} Tc-Leucoscan in the evaluation of inflammatory bowel disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1098-1098.	3.3	3
188	Anti- <i>Saccharomyces cerevisiae</i> mannan antibodies and antineutrophil cytoplasmic autoantibodies in Greek patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 449-454.	0.2	3
189	Mean platelet volume: a useful marker of inflammatory bowel disease activity. <i>American Journal of Gastroenterology</i> , 2001, 96, 776-781.	0.2	279
190	Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 1415-1419.	0.8	38
191	Assaying of Tumor Necrosis Factor α , Complement Factors, and α -1-Antitrypsin in the Diagnosis of Malignant Serous Effusions. <i>American Journal of Oncology: Cancer Clinical Trials</i> , 2001, 24, 562-565.	0.6	8
192	Unraveling the Mechanisms of Thrombosis in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 1325-1327.	0.2	26
193	Anti- <i>Saccharomyces Cerevisiae</i> Mannan Antibodies and Antineutrophil Cytoplasmic Autoantibodies in Greek Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 449-454.	0.2	70
194	Idiopathic fibrosing pancreatitis and Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 1021-1024.	0.8	16
195	Hyperhomocysteinemia in Greek patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2000, 45, 2347-2351.	1.1	51
196	Elevated Thrombopoietin Serum Levels in Patients With Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 3478-3481.	0.2	37
197	Resistance to activated protein C and low levels of free protein S in Greek patients with inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 190-194.	0.2	91
198	Role of Thrombotic Vascular Risk Factors in Inflammatory Bowel Disease. <i>Digestive Diseases</i> , 2000, 18, 161-167.	0.8	35

#	ARTICLE	IF	CITATIONS
199	Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. <i>American Journal of Gastroenterology</i> , 2000, 95, 171-176.	0.2	124
200	Hyperhomocysteinemia in greek patients with inflammatory bowel disease. <i>Gastroenterology</i> , 2000, 118, A314.	0.6	1
201	Ulcerative colitis associated with primary biliary cirrhosis. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1953-1956.	1.1	35
202	Appendectomy, tonsillectomy, and risk of inflammatory bowel disease. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 225-230.	0.7	57
203	Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2507-2512.	1.1	81
204	Association between ulcerative colitis and systemic lupus erythematosus. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 437-440.	0.8	19
205	Somatostatin for acute severe bleeding from portal hypertensive gastropathy. <i>European Journal of Gastroenterology and Hepatology</i> , 1998, 10, 509-512.	0.8	64
206	Chemoprevention of colorectal cancer in inflammatory bowel disease? A potential role for folate. <i>Italian Journal of Gastroenterology and Hepatology</i> , 1998, 30, 421-5.	0.5	10
207	A Prospective Epidemiologic Study of Crohn's Disease in Heraklion, Crete Incidence over a 5-Year Period. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 599-603.	0.6	48
208	Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 105-10.	0.8	9
209	Ulcerative colitis is as common in Crete as in northern Europe: a 5-year prospective study. <i>European Journal of Gastroenterology and Hepatology</i> , 1996, 8, 893-8.	0.8	27
210	Immunogenetics of Cytokines: Relevance for Future Research on Inflammatory Bowel Disease. <i>Scandinavian Journal of Gastroenterology</i> , 1995, 30, 1139-1146.	0.6	7